JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Formerly known as GW Research Limited, the company operates as the UK biotechnology research and development subsidiary of the Nasdaq-listed biopharmaceutical group Jazz Pharmaceuticals plc, focusing on oncology and neuroscience medicines.
Get an alert when JAZZ PHARMACEUTICALS RESEARCH UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£230M
+758% vs 2023
Employees
294
-15.5% vs 2023
Profit before tax
£77M
+25.6% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £296,457,000 | £239,673,000 | -19.2% | |
| Operating profit | £60,599,000 | £78,234,000 | +29.1% | |
| Profit before tax | £61,607,000 | £77,389,000 | +25.6% | |
| Net profit | £61,607,000 | £191,257,000 | +210.4% | |
| Cash | — | — | — | |
| Total assets less current liabilities | £31,202,000 | £234,114,000 | +650.3% | |
| Net assets | £26,775,000 | £229,735,000 | +758% | |
| Equity | £26,775,000 | £229,735,000 | +758% | |
| Average employees | 348 | 294 | -15.5% | |
| Wages | £28,882,000 | £28,633,000 | -0.9% | |
| Directors' remuneration | £2,345,000 | £2,819,000 | +20.2% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 20.4% | 32.6% | |
| Net margin | 20.8% | 79.8% | |
| Return on capital employed | 194.2% | 33.4% | |
| Current ratio | 1.06x | 1.84x | |
| Interest cover | 10.45x | 18.26x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 4 times since incorporation
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED 2023-11-20 → present
- GW RESEARCH LIMITED 2011-10-03 → 2023-11-20
- G-PHARM LIMITED 1999-04-21 → 2011-10-03
- G W PHARMACEUTICALS LIMITED 1998-05-18 → 1999-04-21
- TITANITE LIMITED 1995-09-28 → 1998-05-18
Audit & accounting basis
- Accounting basis
- FRS 101 Reduced Disclosure Framework
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements ('the going concern period').”
Significant events
- “There have been no events or circumstances since the balance sheet date that would significantly affect the Company.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 22 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PATEL, Alkesh | Secretary | 2024-04-03 | — | — |
| MARCHETTI, Luca Giacomo | Director | 2023-04-28 | Jun 1972 | Italian |
| PETERSEN, Jessica | Director | 2024-10-01 | Sep 1981 | British |
| SPACKMAN, David James | Director | 2023-01-13 | Jan 1976 | British |
Show 22 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BROWN, Michael Terence | Secretary | 1998-05-14 | 1998-05-19 |
| DOODY, Aislinn Jane | Secretary | 2023-01-13 | 2024-04-03 |
| GEORGE, Adam David | Secretary | 2008-01-30 | 2020-12-18 |
| HATCHARD, John Rayner | Secretary | 1998-05-19 | 2000-11-07 |
| LAUGHTON, Jonathan Michael | Secretary | 2001-10-08 | 2008-01-30 |
| THOMSON, Alison Jean | Secretary | 1995-09-28 | 1998-05-14 |
| WARD, Iain Stuart | Secretary | 2020-12-18 | 2023-01-13 |
| MAWLAW SECRETARIES LIMITED | Corporate Secretary | 2000-11-07 | 2001-10-08 |
| WATERLOW SECRETARIES LIMITED | Corporate Nominee Secretary | 1995-09-28 | 1995-09-28 |
| BAILEY, Roger Piers Marden | Director | 1998-05-14 | 1998-05-19 |
| CAMPBELL, Adrian | Director | 2020-12-18 | 2023-01-01 |
| GEORGE, Adam David | Director | 2008-01-30 | 2020-12-18 |
| GOVER, Justin David | Director | 1999-01-12 | 2015-06-30 |
| GUY, Geoffrey William, Dr | Director | 1998-05-19 | 2021-05-05 |
| HATCHARD, John Rayner | Director | 1998-05-19 | 2002-09-20 |
| KIRK, David Francis | Director | 2001-09-10 | 2012-06-01 |
| PEARCE, Samantha Jane Laura | Director | 2023-01-13 | 2024-10-01 |
| THOMSON, Brian | Director | 1995-09-28 | 1998-05-14 |
| TOVEY, Christopher John | Director | 2012-10-01 | 2022-10-27 |
| WARD, Iain Stuart | Director | 2020-12-18 | 2023-01-13 |
| WRIGHT, Stephen, Dr | Director | 2011-09-28 | 2017-05-01 |
| WATERLOW NOMINEES LIMITED | Corporate Nominee Director | 1995-09-28 | 1995-09-28 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Gw Pharmaceuticals Ltd | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 176 total filings
Material constitutional events — rename, articles re-file, resolution
- 2023-11-20 CERTNM Certificate change of name company PDF
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-11-21 | MR05 | mortgage | Mortgage charge part both with charge number | |
| 2025-11-21 | MR05 | mortgage | Mortgage charge part both with charge number | |
| 2025-11-21 | MR05 | mortgage | Mortgage charge part both with charge number | |
| 2025-10-03 | AA | accounts | Accounts with accounts type full | |
| 2025-01-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-12-30 | AA | accounts | Accounts with accounts type full | |
| 2024-11-27 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-10-02 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-04-15 | AP03 | officers | Appoint person secretary company with name date | |
| 2024-04-15 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-01-23 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-01-17 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-01-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-01-08 | AA | accounts | Accounts with accounts type full | |
| 2023-11-21 | AD01 | address | Change registered office address company with date old address new address | |
| 2023-11-20 | CERTNM | change-of-name | Certificate change of name company | |
| 2023-06-26 | CH01 | officers | Change person director company with change date | |
| 2023-05-11 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.